u," Recombinant gamma-interferon (2 mg/sq m) was administered intravenously twice weekly in 8-week courses to 14 patients with recurrent gliomas. Computerized tomography (CT) evidence of response was seen in only one patient, and stabilization for 12 to 86 weeks was recorded in three. This was a disappointing result, particularly in a series of patients with relatively small initial tumor volumes (less than 50 cu mm on enhanced CT) and Karnofsky functional ratings of 70 or higher. In addition, several instances of toxicity potentially attributable to gamma-interferon were observed.
G
AMMA-INTERFERON has been reported to activate the specific cytotoxicity of lymphocytes against glioma cells in the presence of interleukin-2, 3 to inhibit in vitro growth of glioma cell lines, 25 and to increase the human leukocyte antigen (HLA) DR surface antigens and cytoplasmic HLA-DR-specific ribonucleic acid (RNA) of glioma cells in vitro. 26 '27 Smith and his coworkers administered postoperative intraventricular gamma-interferon to three patients, beginning 2 months after radiotherapy; one of their patients experienced a gradual reduction in tumor size over 9 months, as observed on computerized tomography (CT) scans (unpublished data). We have previously reported the clinical efficacy of alpha-interferon in the treatment of patients with recurrent gliomas, 12 and are now reporting our less favorable clinical experience with gamma-interferon.
Clinical Material and Methods
This study was designed to evaluate the toxicity and possible efficacy of recombinant gamma-interferon (Immuneron) administered systemically to adult patients with recurrent progressive gliomas. To enhance the possibility of efficacy, based upon previous experience with alpha-interferon,~2 only patients with enhancing CT tumor volumes of less than 50 cu cm were treated. Each patient had a Karnofsky rating of 70 or higher. Fifteen patients were admitted into the study. One patient (Case 105) received only two injections of gamma-interferon because of hypotension. The characteristics of the patients are shown in Table 1 . The dose schedule for gamma-interferon was 2 mg/sq m twice weekly (Monday and Thursday or Tuesday and Friday) for 8 weeks. Unless progression of disease was documented, this schedule was repeated twice, followed by maintenance treatment with 2 mg/sq m once weekly until progression. Patients were hospitalized for the 1 st week of treatment and were treated as outpatients thereafter.
Baseline evaluations prior to beginning treatment included contrast-enhanced CT scanning, neurological examination, Karnofsky functional rating, complete blood count with differential, platelet count, electrolyte evaluation, liver and renal profile, serum glucose level, urinalysis, electrocardiography, and chest x-ray film. Each patient was followed serially with contrast-enhanced CT scanning, Karnofsky rating, and neurological examination monthly as well as repeat blood and urine studies throughout the treatment period.
Efficacy of treatment was determined by comparing the enhancing tumor volumes on serial CT scans. The CT scans were determined to indicate response when there was 25% or greater reduction in the enhancing tumor volume compared to the baseline CT scan in the absence of any increase in steroid administration. Stable CT scans were those in which the enhancing tumor volume had less than a 25% increase or decrease in size compared to baseline. Progression of disease on CT scans was determined when the enhancing tumor volume increased 25% or more compared to baseline in * Karnofsky functional rating at start of interferon therapy. t RT = radiation therapy; WB = RT dose to whole brain; LF = RT dose to limited field.
the absence of a reduction in steroid administration. Time to treatment failure and length of survival were also computed from the time gamma-interferon was initiated. Serial neurological examinations and Karnofsky ratings were recorded and considered in the overall evaluation of each patient.
Results
Ten of the 15 patients had glioblastomas, two had anaplastic astrocytomas, one had an ependymoma, one had an astrocytoma, and one had an oligodendroglioma ( Table 1 ). The mean patient age was 45.6 years, mean Karnofsky rating was 93, and the mean tumor volume was 21 cu cm. The median time to treatment failure of the 14 patients who had documented progression was 7 weeks (mean 12.7 weeks). The median survival time for all 15 patients was 24 weeks. Based upon the CT scan at 8 weeks after beginning treatment, 11 patients exhibited tumor progression, three (Cases 103, 114, and l l5) had remained stable for 86, 71+, and 12 weeks, respectively, and one (Case 108) responded, but for only 12 weeks. These results are summarized in Table  2 . As of December 3 l, 1987, four patients are alive but none is being treated with interferon at this time.
The most serious toxicity (Table 3) definitely attributable to gamma-interferon was hypotension in one patient. This patient (Case 105) developed a systolic blood pressure of 70 mm Hg within 1 hour after corn- pletion of the first infusion, which was confirmed by a second infusion later that week. This patient was not treated further with interferon and died of tumor progression within 4 weeks. All other toxicities were well tolerated and transient, with one exception. That patient (Case 1 10) showed CT evidence of tumor progression after 4 weeks of treatment, but remained neuro- logically stable. Although all blood studies were normal during his prior treatment, 4 days following the last gamma-interferon infusion he became ill with a sore throat, chills, and a fever of 103*F. He was admitted to another hospital, where a neurological examination, admission blood and chest x-ray studies, and bacterial cultures were unremarkable. He was treated with intravenous fluids, cefamandole, promethazine, and acetaminophen in addition to his usual dose of dexamethasone and carbamazepine. One week after admission, the patient's condition deteriorated with evidence of acute renal failure (uric acid 13 mg/dl, creatinine 13.4 mg/dl, blood urea nitrogen 116 mg/dl, potassium 6.9 mEq/liter) and epistaxis, despite no vascular hypertension, a normal blood platelet level, and no coagulopathy. He died 1 day later. Although no autopsy was performed, the cause of death was considered to be acute renal failure of uncertain origin.
Discussion
In recent years, a number of biological response modifiers have emerged as potentially useful agents in the clinical management of patients with cancer. The lymphokines include interferons which originally were subdivided into those designated as virally induced, such as leukocyte-derived interferon (alpha) and fibroblast-derived interferon (beta), and the immune interferon (gamma). At the present time there are recombinant deoxyribonucleic acid (DNA)-derived forms of these interferons which continue to be actively studied, both experimentally and clinically as regards their inhibitory activity upon cancer cell growth as well as their stimulatory activity for the immune system. Beta-interferon was the first lymphokine to be studied clinically in patients with gliomas. It has been shown to inhibit replication of human glioma cells in vitrolO, l 1.13,29,30 and implanted in nude mice. 19 '24 This form of interferon also retards growth of human glioma cells in vitro 22 and in nude mice. 4 In the largest clinical series, we reported CT evidence of response in seven of 17 patients with recurrent gliomas who received 900 x 105 U/sq m intravenously or intramuscularly over 8 weeks. 12 Gamma-interferon has been shown in vitro to increase the HLA-DR antigens on cell surfaces and to activate lymphocytes to produce specific cytotoxicity in the presence of interleukin-2. 3' 26"27 Until now, the only clinical use of gamma-interferon in glioma patients appears to be that of Smith, et al., who observed a reduction in tumor size on postoperative CT scans during radiotherapy and intraventricular interferon administration in one of three patients so treated (unpublished data). Our results with recombinant gammainterferon are disappointing, with only one patient, an individual with an oligodendroglioma, showing CT evidence of response. Evidence of treatment failure was usually seen by the time of completion of an 8-week course of therapy, and the median survival time for the 15 patients was 24 weeks. Most of the toxicities observed were anticipated, including vascular hypotension which, although transient, was severe enough to abandon further interferon therapy in one patient. The precise cause of renal failure with death of one patient after 4 weeks of treatment is unclear, since no evidence of renal toxicity to any extent whatsoever was found in any other treated patient.
Unless gamma-interferon is shown to have efficacy when used in combination with other interferons 26 or with chemotherapeutic agents, it would likely be prudent to concentrate preclinical and clinical studies on alpha-or beta-interferon.
